Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern.

Cappelli LV, Meggendorfer M, Dicker F, Jeromin S, Hutter S, Kern W, Haferlach T, Haferlach C, Höllein A.

Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0502-0. [Epub ahead of print] No abstract available.

PMID:
31209279
2.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.

Janjetovic S, Asemissen AM, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P.

Tumori. 2019 Apr 1:300891619839473. doi: 10.1177/0300891619839473. [Epub ahead of print]

PMID:
30935343
3.

Evidence of clonality in cases of hypereosinophilia of undetermined significance.

Pohlkamp C, Vetro C, Dicker F, Meggendorfer M, Kern W, Haferlach C, Haferlach T.

Leuk Lymphoma. 2019 Aug;60(8):2071-2074. doi: 10.1080/10428194.2018.1564825. Epub 2019 Jan 18. No abstract available.

PMID:
30656986
4.

International external quality assurance of JAK2 V617F quantification.

Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J, Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, Girodon F, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H, Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-Lenczowska D, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, Sudarikov A, Hermouet S, Pallisgaard N.

Ann Hematol. 2019 May;98(5):1111-1118. doi: 10.1007/s00277-018-3570-8. Epub 2018 Dec 8.

5.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

Höllein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Blood Adv. 2018 Nov 27;2(22):3118-3125. doi: 10.1182/bloodadvances.2018023432.

6.

Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing.

Stengel A, Nadarajah N, Haferlach T, Dicker F, Kern W, Meggendorfer M, Haferlach C.

Leukemia. 2018 May;32(5):1229-1238. doi: 10.1038/s41375-017-0002-z. Epub 2018 Feb 26. No abstract available.

PMID:
29479069
7.

Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Baer C, Dicker F, Kern W, Haferlach T, Haferlach C.

Leukemia. 2017 Jun;31(6):1355-1362. doi: 10.1038/leu.2016.330. Epub 2016 Nov 14.

PMID:
27840426
8.

Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations.

Jeromin S, Haferlach C, Dicker F, Alpermann T, Haferlach T, Kern W.

Leukemia. 2016 Nov;30(11):2251-2253. doi: 10.1038/leu.2016.189. Epub 2016 Jul 14. No abstract available.

PMID:
27411488
9.

Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia.

Weber S, Haferlach C, Jeromin S, Nadarajah N, Dicker F, Noël L, Zenger M, Alpermann T, Kern W, Haferlach T, Schnittger S.

Genes Chromosomes Cancer. 2016 Feb;55(2):148-57. doi: 10.1002/gcc.22321. Epub 2015 Nov 6.

PMID:
26542308
10.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.

Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, Schmid C, Aul C, Staib P, Wendtner CM, Schmitz N, Haferlach C, Haferlach T.

Haematologica. 2016 Feb;101(2):e55-8. doi: 10.3324/haematol.2015.133819. Epub 2015 Oct 15. No abstract available.

11.

Young Man with Sore Throat, Headache, and Rash.

Dicker F, Walsh R, May IC.

J Emerg Med. 2016 Feb;50(2):e99-e101. doi: 10.1016/j.jemermed.2015.08.012. Epub 2015 Oct 9. No abstract available.

PMID:
26443642
12.

Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia.

Truger MS, Jeromin S, Weissmann S, Dicker F, Kern W, Schnittger S, Haferlach T, Haferlach C.

Br J Haematol. 2015 Jan;168(1):153-6. doi: 10.1111/bjh.13077. Epub 2014 Aug 19. No abstract available.

PMID:
25135300
13.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, Kuznia S, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2015 Mar;29(3):660-7. doi: 10.1038/leu.2014.243. Epub 2014 Aug 11.

PMID:
25110071
14.

Quantification of rare NPM1 mutation subtypes by digital PCR.

Bacher U, Dicker F, Haferlach C, Alpermann T, Rose D, Kern W, Haferlach T, Schnittger S.

Br J Haematol. 2014 Dec;167(5):710-4. doi: 10.1111/bjh.13038. Epub 2014 Jul 18. No abstract available.

PMID:
25039748
15.

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases.

Fasan A, Haferlach C, Kohlmann A, Dicker F, Eder C, Kern W, Haferlach T, Schnittger S.

Haematologica. 2014 Feb;99(2):e20-1. doi: 10.3324/haematol.2013.099754. No abstract available.

16.

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.

Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, Fasan A, Kohlmann A, Meggendorfer M, Haferlach C, Kern W, Haferlach T, Schnittger S.

Blood Cancer J. 2014 Jan 10;4:e173. doi: 10.1038/bcj.2013.71.

17.

Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization.

Kern W, Bacher U, Schnittger S, Dicker F, Alpermann T, Haferlach T, Haferlach C.

Br J Haematol. 2014 Feb;164(4):565-9. doi: 10.1111/bjh.12652. Epub 2013 Nov 14.

PMID:
24236747
18.

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, Alpermann T, Roller A, Kohlmann A, Haferlach T, Kern W, Schnittger S.

Leukemia. 2014 Jan;28(1):108-17. doi: 10.1038/leu.2013.263. Epub 2013 Sep 12.

PMID:
24113472
19.

The role of different genetic subtypes of CEBPA mutated AML.

Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S.

Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23.

PMID:
24056881
20.

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.

Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, Roller A, Kern W, Haferlach C, Schnittger S, Haferlach T.

Leukemia. 2014 Jan;28(1):129-37. doi: 10.1038/leu.2013.239. Epub 2013 Aug 20.

PMID:
23958918
21.

A novel recurrent AML1-ETO fusion: tight in vivo association with BCR-ABL1.

Solari L, Bauer T, Dicker F, Haferlach C, Grießhammer M, Schnittger S, Becker H, Lübbert M.

Leukemia. 2013 Jun;27(6):1397-400. doi: 10.1038/leu.2013.53. Epub 2013 Feb 21. No abstract available.

PMID:
23426164
22.

Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia.

Grossmann V, Bacher U, Kohlmann A, Butschalowski K, Roller A, Jeromin S, Dicker F, Kern W, Schnittger S, Haferlach T, Haferlach C.

Blood Cancer J. 2012 Aug 31;2:e86. doi: 10.1038/bcj.2012.34. No abstract available.

23.

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).

Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, Kohlmann A, Alpermann T, Yoshida K, Ogawa S, Koeffler HP, Kern W, Haferlach C, Schnittger S.

Blood. 2012 Oct 11;120(15):3080-8. doi: 10.1182/blood-2012-01-404863. Epub 2012 Aug 23.

24.

A novel hierarchical prognostic model of AML solely based on molecular mutations.

Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, Schmid C, Wendtner CM, Staib P, Serve H, Kreuzer KA, Kern W, Haferlach T, Haferlach C.

Blood. 2012 Oct 11;120(15):2963-72. doi: 10.1182/blood-2012-03-419622. Epub 2012 Aug 20.

PMID:
22915647
25.

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.

Fasan A, Eder C, Haferlach C, Grossmann V, Kohlmann A, Dicker F, Kern W, Haferlach T, Schnittger S.

Leukemia. 2013 Feb;27(2):482-5. doi: 10.1038/leu.2012.174. Epub 2012 Jul 3. No abstract available.

PMID:
22814295
26.

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.

Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, Eder C, Kohlmann A, Grossmann V, Kowarsch A, Kern W, Haferlach C, Haferlach T.

Haematologica. 2012 Dec;97(12):1890-4. doi: 10.3324/haematol.2012.065375. Epub 2012 Jun 24.

27.

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.

Schnittger S, Bacher U, Eder C, Dicker F, Alpermann T, Grossmann V, Kohlmann A, Kern W, Haferlach C, Haferlach T.

Haematologica. 2012 Oct;97(10):1582-5. doi: 10.3324/haematol.2012.064683. Epub 2012 Apr 17.

28.

Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.

Schnittger S, Bacher U, Haferlach T, Wendland N, Ulke M, Dicker F, Grossmann V, Haferlach C, Kern W.

Blood. 2012 Mar 29;119(13):3151-4. doi: 10.1182/blood-2011-10-383323. Epub 2012 Feb 13.

PMID:
22331186
29.

Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.

Kern W, Bacher U, Haferlach C, Dicker F, Alpermann T, Schnittger S, Haferlach T.

Br J Haematol. 2012 Apr;157(1):86-96. doi: 10.1111/j.1365-2141.2011.09010.x. Epub 2012 Jan 9.

PMID:
22224978
30.

Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.

Kern W, Bacher U, Haferlach C, Alpermann T, Dicker F, Schnittger S, Haferlach T.

Cytometry B Clin Cytom. 2012 May;82(3):145-50. doi: 10.1002/cyto.b.21002. Epub 2011 Dec 5.

31.

Landscape of TET2 mutations in acute myeloid leukemia.

Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A.

Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25.

PMID:
22116554
32.

The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML.

Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W, Schnittger S.

Leukemia. 2011 May;25(5):874-7. doi: 10.1038/leu.2011.5. Epub 2011 Feb 1. No abstract available.

PMID:
21283084
33.

Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure.

Grossmann V, Kohlmann A, Klein HU, Schindela S, Schnittger S, Dicker F, Dugas M, Kern W, Haferlach T, Haferlach C.

Leukemia. 2011 Apr;25(4):671-80. doi: 10.1038/leu.2010.309. Epub 2011 Jan 21.

PMID:
21252984
34.

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.

Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J, Kern W, Haferlach T.

Leukemia. 2011 Apr;25(4):615-21. doi: 10.1038/leu.2010.299. Epub 2011 Jan 14.

PMID:
21233837
35.

An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling.

Flach J, Dicker F, Schnittger S, Schindela S, Kohlmann A, Haferlach T, Kern W, Haferlach C.

Leukemia. 2011 Apr;25(4):713-8. doi: 10.1038/leu.2010.304. Epub 2011 Jan 14. No abstract available.

PMID:
21233836
36.

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.

Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, Haferlach C, Haferlach T.

Blood. 2011 Feb 24;117(8):2348-57. doi: 10.1182/blood-2009-11-255976. Epub 2010 Dec 9.

PMID:
21148331
37.

Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.

Reindl L, Bacher U, Dicker F, Alpermann T, Kern W, Schnittger S, Haferlach T, Haferlach C.

Br J Haematol. 2010 Oct;151(1):25-36. doi: 10.1111/j.1365-2141.2010.08299.x. Epub 2010 Jul 22.

PMID:
20649559
38.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, Dicker F, Schnittger S, Dugas M, Kern W, Haferlach C, Haferlach T.

J Clin Oncol. 2010 Aug 20;28(24):3858-65. doi: 10.1200/JCO.2009.27.1361. Epub 2010 Jul 19.

PMID:
20644105
39.

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.

Schnittger S, Bacher U, Dicker F, Kern W, Alpermann T, Haferlach T, Haferlach C.

Genes Chromosomes Cancer. 2010 Oct;49(10):910-8. doi: 10.1002/gcc.20801.

PMID:
20607847
40.

Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.

Haferlach C, Dicker F, Weiss T, Schnittger S, Beck C, Grote-Metke A, Oruzio D, Kern W, Haferlach T.

Genes Chromosomes Cancer. 2010 Sep;49(9):851-9. doi: 10.1002/gcc.20794.

PMID:
20552631
41.

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.

Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W, Haferlach T, Schnittger S.

Leukemia. 2010 Aug;24(8):1528-32. doi: 10.1038/leu.2010.124. Epub 2010 Jun 3. No abstract available.

PMID:
20520634
42.

AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions.

Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W, Schnittger S, Haferlach T.

Leukemia. 2010 May;24(5):1065-9. doi: 10.1038/leu.2010.22. Epub 2010 Feb 18. No abstract available.

PMID:
20164853
43.

Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.

Flach J, Dicker F, Schnittger S, Kohlmann A, Haferlach T, Haferlach C.

Haematologica. 2010 Mar;95(3):518-9. doi: 10.3324/haematol.2009.013631. Epub 2009 Nov 10. No abstract available.

44.

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T.

Blood. 2009 Sep 10;114(11):2220-31. doi: 10.1182/blood-2009-03-213389. Epub 2009 Jul 8.

PMID:
19587375
45.

Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.

Kern W, Dicker F, Schnittger S, Haferlach C, Haferlach T.

Cytometry B Clin Cytom. 2009 Nov;76(6):385-93. doi: 10.1002/cyto.b.20483.

46.

Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).

Munker R, Nordberg ML, Veillon D, Williams BJ, Roggero A, Kern W, Dicker F, Haferlach T.

Leuk Res. 2009 Oct;33(10):1405-8. doi: 10.1016/j.leukres.2009.04.008. Epub 2009 May 2.

PMID:
19414191
47.

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.

Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, Kern W, Haferlach T, Haferlach C.

Leukemia. 2009 Jan;23(1):117-24. doi: 10.1038/leu.2008.274. Epub 2008 Oct 9.

PMID:
18843282
48.

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype.

Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T.

Leukemia. 2008 Aug;22(8):1539-41. doi: 10.1038/leu.2008.143. Epub 2008 Jun 5.

PMID:
18528419
49.

Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.

Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T.

Leukemia. 2007 Dec;21(12):2442-51. Epub 2007 Sep 6.

PMID:
17805327
50.

Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.

Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S.

Blood. 2007 Aug 15;110(4):1308-16. Epub 2007 May 7.

PMID:
17485549

Supplemental Content

Loading ...
Support Center